Form 4: Beam Therapeutics CLO Sells Shares for Tax Obligations
Insider Transaction Report
Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 373 shares of common stock to cover tax withholding obligations related to RSU vesting.
Summary
- Christine Bellon, Chief Legal Officer and Director of Beam Therapeutics Inc. (BEAM), reported a transaction involving the company's common stock.
- On October 1, 2025, Bellon sold 373 shares of common stock at a price of $24.53 per share.
- The sale was non-discretionary and executed to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs).
- These RSUs were granted to Bellon under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021.
- The transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Bellon on May 19, 2023.
- Following this transaction, Bellon beneficially owns 116,921 shares of Beam Therapeutics common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, executed under a pre-established 10b5-1 plan. It does not reflect a change in management's outlook or provide new information about the company's performance, thus indicating a neutral sentiment.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes, which is common for executives receiving equity compensation. It does not provide insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 09/30/2021 | Date of grant for restricted stock units (RSUs) under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 05/19/2023 | Date the Rule 10b5-1 trading plan was adopted by Christine Bellon. |
| 10/01/2025 | Date of the reported transaction where 373 shares of common stock were sold. |
| 10/03/2025 | Date the Form 4 was signed by Christine Bellon. |
Recommendation
holdThe reported transaction is a mandatory sale of shares by an insider to cover tax obligations upon the vesting of restricted stock units, executed under a pre-arranged 10b5-1 plan. Such a transaction is not indicative of the insider's discretionary view on the company's future prospects or a signal for market participants to buy or sell. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.
Keywords
Beam Therapeutics, BEAM, Christine Bellon, Chief Legal Officer, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.